Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Rémy, Boussageon"'
Publikováno v:
BMJ Medicine, Vol 1, Iss 1 (2022)
Objective To evaluate the impact of conducting all possible pooled analyses across different combinations of randomised controlled trials and endpoints.Design Multiverse analysis, consisting of numerous pooled analyses of individual participant data.
Externí odkaz:
https://doaj.org/article/ec4f639cbaec4516bd3084c987be5453
Autor:
Bruno Giraudeau, Estelle Boivin, Vincent Camus, Agnes Caille, Olivier Saint-Lary, Jean-Pierre Lebeau, Stéphanie Sidorkiewicz, Denis Pouchain, Maeva Jego, Sophie Sun, Denis Angoulvant, Wissam El-Hage, Sébastien Bruel, Clarisse Dibao-Dina, Julie Léger, Isabelle Ettori-Ajasse, Juliette Chambe, Karim Abou-Mrad-Fricquegnon, Baptiste Motte, Benoit Chiron, Cam-Anh Khau, Tiphanie Bouchez, Maria Ghali, Leslie Guillon-Grammatico, Emeline Laurent, Rémy Boussageon
Publikováno v:
BMJ Open, Vol 12, Iss 7 (2022)
Objectives The first COVID-19 lockdown led to a significantly reduced access to healthcare, which may have increased decompensations in frail patients with chronic diseases, especially older patients living with a chronic cardiovascular disease (CVD)
Externí odkaz:
https://doaj.org/article/3cf292718a6d4d8cb004beb4c055ec9b
Autor:
Elodie Charuel, Thibault Menini, Sabrina Bedhomme, Bruno Pereira, Nathalie Piñol‐Domenech, Suzy Bouchant, Rémy Boussageon, Sylvaine Bœuf‐Gibot, Helene Vaillant‐Roussel
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart failure, with a focus on important patient outcomes. A systematic review was conducted of double‐blind randomized controlled trials (RCTs) compari
Externí odkaz:
https://doaj.org/article/fa5b5a2ee1cc43b18969c5f63d2579ca
Publikováno v:
PLoS Medicine, Vol 18, Iss 8 (2021)
Florian Naudet and co-authors propose a pathway involving registered criteria for evaluation and approval of new drugs.
Externí odkaz:
https://doaj.org/article/7ee27d57de9c4978aafdedbdf0fc451a
Autor:
Rémy Boussageon, Jeremy Howick, Raphael Baron, Florian Naudet, Bruno Falissard, Ghina Harika‐Germaneau, Issa Wassouf, François Gueyffier, Nemat Jaafari, Clara Blanchard
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 2022, ⟨10.1111/bcp.15345⟩
British Journal of Clinical Pharmacology, 2022, ⟨10.1111/bcp.15345⟩
International audience; AIM: The placebo effect and the specific effect are often thought to add up (additive model). Whether additivity holds can dramatically influence the external validity of a trial. This assumption of additivity was tested by Kl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::613b214a2cd198217aece37b3d3b3e6e
https://doi.org/10.1111/bcp.15345
https://doi.org/10.1111/bcp.15345
Autor:
Anaëlle Collin, François Mion, Amaniel Kefleyesus, Corinne Beets, Nemat Jaafari, Rémy Boussageon
Publikováno v:
Helicobacter. 28
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b81ba320d1faa6ebf39b0e7178ff375e
https://doi.org/10.1111/hel.12952
https://doi.org/10.1111/hel.12952
Autor:
Mor Fall, Guillaume Grenet, Hai-Ha Le, Behrouz Kassaï, Jean-Christophe Lega, Rémy Boussageon, Sabine Mainbourg, Ivanny Marchant, Johanne Gafsi, Amadou Moctar Dieye, François Gueyffier
Publikováno v:
Therapies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d42a894fd71f6f78d045cd20ae6506aa
https://doi.org/10.1016/j.therap.2023.01.011
https://doi.org/10.1016/j.therap.2023.01.011
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.
Autor:
Guillaume Grenet, Shams Ribault, Giao Bao Nguyen, Faustine Glais, Augustin Metge, Thomas Linet, Behrouz Kassai-Koupai, Catherine Cornu, Théodora Bejan-Angoulvant, Sylvie Erpeldinger, Rémy Boussageon, Aurore Gouraud, Fabrice Bonnet, Michel Cucherat, Philippe Moulin, François Gueyffier
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0217701 (2019)
BackgroundThe last international consensus on the management of type 2 diabetes (T2D) recommends SGLT-2 inhibitors or GLP-1 agonists for patients with clinical cardiovascular (CV) disease; metformin remains the first-line glucose lowering medication.
Externí odkaz:
https://doaj.org/article/b80e052c1b1248caae71b05d7b6683f6
Publikováno v:
Infectious Diseases Now. 53:104716
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::248ca4f7fb446e6c72d408d2b228a989
https://doi.org/10.1016/j.idnow.2023.104716
https://doi.org/10.1016/j.idnow.2023.104716
Autor:
Nemat Jaafari, Hélène Vaillant-Roussel, Benoit Tudrej, Denis Pouchain, Elodie Tawil, Caroline Huas, Rémy Boussageon, Christine Maynié-François, Florian Naudet
Publikováno v:
Alternative and Complementary Therapies
Alternative and Complementary Therapies, 2021, 76 (5), pp.403-408. ⟨10.1016/j.therap.2020.09.004⟩
Alternative and Complementary Therapies, Mary Ann Liebert, 2020, ⟨10.1016/j.therap.2020.09.004⟩
Alternative and Complementary Therapies, Mary Ann Liebert, 2021, 76 (5), pp.403-408. ⟨10.1016/j.therap.2020.09.004⟩
Alternative and Complementary Therapies, 2021, 76 (5), pp.403-408. ⟨10.1016/j.therap.2020.09.004⟩
Alternative and Complementary Therapies, Mary Ann Liebert, 2020, ⟨10.1016/j.therap.2020.09.004⟩
Alternative and Complementary Therapies, Mary Ann Liebert, 2021, 76 (5), pp.403-408. ⟨10.1016/j.therap.2020.09.004⟩
International audience; OBJECTIVE: The objective of this study was to evaluate the proportion of therapeutics that have proven their efficacy on patient-important outcomes with a high quality of evidence among Cochrane systematic reviews (SRs). METHO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c496123f449b3ed0cccb5ea7d0c28d07
https://doi.org/10.1016/j.therap.2020.09.004
https://doi.org/10.1016/j.therap.2020.09.004